United Health Products, Inc. has received regulatory approval from the Food & Drug Administration for a plan to address violations identified in a Warning Letter issued in March 2025. The FDA has formally approved the company's proposal to collaborate with another U.S. manufacturer and distributor of hemostatic products, where the partner will serve as Sponsor of a new clinical study of UHP's CelluSTAT Hemostatic Gauze.
Under this arrangement, United Health Products will hold an exclusive right of reference to all data from the study for use in a revised Premarket Approval application. This plan allows a study to proceed subject to granting of an Investigational Device Exemption while the company works with the FDA to resolve the Warning Letter. The violations in question occurred during the company's 2019 clinical trial, and the current developments result from 14 months of investigation and discussion with regulatory authorities.
In addition to the clinical study arrangement, the FDA has approved the external audit firm that will conduct a Good Clinical Practices audit of UHP's protocols, procedures and personnel. This audit, recommended by the FDA, will be conducted in the coming months to assess and confirm the company's ability to conduct its own clinical trial in accordance with all applicable FDA regulations. The goal of this comprehensive review is to resolve and lift the Warning Letter through demonstrated compliance.
Bran Thom, UHP's CEO, stated that these milestones provide a clear path to demonstrating the safety and effectiveness of CelluSTAT gauze through a new IDE study. The company is currently in discussions with several established medical device companies regarding the substitute sponsor plan and hopes to enter into a formal collaboration agreement soon. For more information on UHP, visit the company's website at https://www.uhpcorp.com.
The regulatory developments have significant implications for the medical device industry, particularly for companies navigating FDA compliance challenges. The collaborative approach approved by the FDA represents a potential model for resolving regulatory issues while advancing product development. For business leaders in the healthcare technology sector, this case demonstrates the importance of proactive engagement with regulatory bodies and the value of structured corrective action plans.
CelluSTAT Hemostatic Gauze is an all-natural product designed to control mild to moderate bleeding, and UHP is seeking approval to access the human surgical market. The resolution of the Warning Letter and successful completion of the new clinical study could position the company to compete in the growing hemostatic products market. The external audit process also highlights the FDA's emphasis on Good Clinical Practices compliance as a fundamental requirement for medical device companies conducting clinical research.
The company's progress in addressing regulatory concerns comes at a time when the medical device industry faces increasing scrutiny of clinical trial practices and data integrity. Successful resolution of the Warning Letter through the approved plan could restore investor confidence and potentially accelerate the regulatory pathway for CelluSTAT. The developments underscore the complex interplay between regulatory compliance, clinical research partnerships, and market access in the medical technology sector.
